טוען...
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment
Regorafenib (Stivarga, BAY 73-4506; Bayer Pharma AG, Berlin, Germany) is a novel oral multikinase inhibitor that blocks the activity of several protein kinases. However, few guidelines exist for novel biomarkers to select patients who will likely benefit from regorafenib treatment. Metastatic colore...
שמור ב:
| הוצא לאור ב: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
SAGE Publications
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7649869/ https://ncbi.nlm.nih.gov/pubmed/33224274 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920965842 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|